文献速递妇科肿瘤

BRCA1与BRCA2突变携带者的子宫癌风险

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
PubMed 文献 · Eur J Cancer · 2017-08-10

这项多中心前瞻性队列研究评估BRCA1/2突变携带者子宫癌风险,828名合格女性中位随访9.0年发生5例子宫癌,预期2.04例(SIR=2.45,95%CI 0.80-5.72,P=0.11),BRCA1和BRCA2分别SIR=2.87和2.01,均未达统计学显著,结论不支持常规预防性子宫切除术。

要点

  • 828名BRCA1/2突变携带者中位随访9.0年,子宫癌SIR=2.45(95%CI 0.80-5.72,P=0.11),未达统计学显著。
  • BRCA1携带者SIR=2.87(95%CI 0.59-8.43,P=0.18),BRCA2携带者SIR=2.01(95%CI 0.24-7.30,P=0.52),均未达统计学显著。
  • 所有子宫癌均为子宫内膜样亚型、FIGO I-II期,未报告浆液性子宫癌。

核心结论

  • 研究结果与多数其他报告一致,不支持对BRCA1和BRCA2突变携带者常规行预防性子宫切除术。

研究设计与样本

  • 多中心前瞻性队列研究,纳入kConFab队列中入组时有子宫且无子宫癌史的BRCA1/2突变携带者,收集流行病学、生活方式和临床数据并每三年更新,随访至死亡或末次接触。

主要发现

  • 1111名突变携带者中排除278例既往子宫切除、2例既往子宫癌和3例非居民后,828名合格女性中位随访9.0年发生5例子宫癌,预期2.04例(SIR=2.45;95%CI 0.80-5.72;P=0.11)。
  • 438名BRCA1携带者发生3例子宫癌,预期1.04例(SIR=2.87;95%CI 0.59-8.43;P=0.18)。
  • 390名BRCA2携带者发生2例子宫癌,预期0.99例(SIR=2.01;95%CI 0.24-7.30;P=0.52)。
  • 所有病例均为子宫内膜样亚型、FIGO I-II期,未报告浆液性子宫癌。

临床怎么用

  • 原文结论为研究结果不支持对BRCA1和BRCA2突变携带者常规行预防性子宫切除术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether BRCA1 and BRCA2 mutation carriers have a clinically relevant elevated risk of uterine cancer has implications for risk-reducing surgery. AIM: This multicentre, prospective cohort study assessed uterine cancer risk for mutation carriers compared with the general population. METHODS: Eligible mutation carriers were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) cohort study, had a uterus present and no history of uterine cancer at cohort entry. Epidemiological, lifestyle and clinical data were collected at cohort entry and updated three-yearly. Cancer events were verified using pathology reports. Follow-up was censored at death or last contact. Relative risk of uterine cancer was estimated using the standardised incidence ratio (SIR), with the expected number of cases determined using population-based data for Australia. RESULTS: Of 1,111 mutation carriers in kConFab, 283 were excluded due to prior hysterectomy (N = 278), prior uterine cancer (N = 2) or being non-residents (N = 3). After a median follow-up of 9.0 years, five incident uterine cancers were reported in the 828 eligible women (419 had prior breast cancer and 160 had prior tamoxifen use), compared to 2.04 expected (SIR = 2.45; 95% confidence interval [CI]: 0.80-5.72; P = 0.11). In 438 BRCA1 mutation carriers and 390 BRCA2 mutation carriers, three and two incident cases of uterine cancer were reported, respectively, compared to 1.04 expected (SIR = 2.87; 95% CI: 0.59-8.43; P = 0.18) and 0.99 expected (SIR = 2.01; 95% CI: 0.24-7.30; P = 0.52), respectively. All cases were endometrioid subtype, International Federation of Gynaecology and Obstetrics stage I-II disease. No serous uterine cancers were reported. CONCLUSIONS: Our findings are consistent with those from most other reports and do not support routine risk-reducing hysterectomy for BRCA1 and BRCA2 mutation carriers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee YC, Milne RL, Lheureux S, et al. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2017. PMID: 28802188. doi:10.1016/j.ejca.2017.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。